Hospital
Sonoma Valley Health Care District
Sonoma Valley Health Care District was paid $9.14M by Medicaid between Jan 2018 and Nov 2024, across 95 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 18% of everything it billed.
33Billing provider infoSONOMA VALLEY HEALTH CARE DISTRICT
SONOMA, CA 95476
SONOMA, CA 95476
33aNPI1710063870assigned 10/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.14M
24GClaims126,646
24DCodes billed95
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#190 of 410
Median peer was paid$6.90M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,303 | $803K | |
| 2019 | 18,458 | $1.07M | |
| 2020 | 13,804 | $1.02M | |
| 2021 | 17,017 | $1.25M | |
| 2022 | 22,527 | $1.72M | |
| 2023 | 21,203 | $1.75M | |
| 2024incomplete | 16,334 | $1.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 18% | 9,533 | 8,147 | $1.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 14,932 | 12,525 | $1.25M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.9% | 8,996 | 2,868 | $811K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 7.4% | 2,272 | 1,086 | $677K |
| 99201 | 5.5% | 2,273 | 1,180 | $506K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.5% | 3,273 | 2,799 | $504K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 4.0% | 1,259 | 1,242 | $364K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 491 | 474 | $343K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.2% | 2,546 | 2,092 | $288K |
| 97139 | 2.9% | 5,567 | 1,187 | $266K | |
| 97750 | 2.5% | 1,449 | 1,401 | $228K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.3% | 423 | 412 | $209K |
83 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 2,365 | $199K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 2,201 | $162K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.5% | 649 | $135K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,551 | $118K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 527 | $117K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 274 | $94K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,237 | $91K |
| J3490 | Unclassified drugs | <1% | 11,899 | $86K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,182 | $81K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,209 | $80K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,050 | $67K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,061 | $56K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,257 | $53K |
| 97010 | <1% | 558 | $50K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 965 | $49K |
| 80053 | Comprehensive metabolic panel | <1% | 5,705 | $47K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,018 | $47K |
| 99070 | <1% | 2,960 | $46K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,309 | $42K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,193 | $38K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 39 | $34K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 156 | $29K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,026 | $24K |
| 81001 | <1% | 4,087 | $20K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 298 | $19K |
| Z7502 | <1% | 500 | $19K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,229 | $19K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,352 | $19K |
| 84484 | <1% | 2,106 | $17K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 88 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 72 | $14K |
| 73221 | <1% | 15 | $13K | |
| 83690 | <1% | 2,360 | $12K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,974 | $12K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 15 | $11K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,452 | $11K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 213 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 318 | $9K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 31 | $8K |
| 83880 | <1% | 320 | $8K | |
| 83605 | <1% | 873 | $7K | |
| 0450 | Emergency room services | <1% | 31 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 71 | $6K |
| 73030 | <1% | 86 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 406 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 850 | $5K |
| 83735 | <1% | 914 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 16 | $5K |
| 73610 | <1% | 61 | $4K | |
| 73630 | <1% | 61 | $4K | |
| 93017 | <1% | 13 | $3K | |
| 81025 | <1% | 627 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 163 | $2K |
| 97165 | <1% | 12 | $2K | |
| 76642 | <1% | 12 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 166 | $2K |
| 85610 | <1% | 415 | $2K | |
| 87040 | <1% | 213 | $2K | |
| 73562 | <1% | 17 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 246 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 79 | $1K |
| 71048 | <1% | 22 | $1K | |
| 73564 | <1% | 14 | $1K | |
| 73110 | <1% | 13 | $1K | |
| 87420 | <1% | 440 | $1K | |
| Z7610 | <1% | 171 | $815.28 | |
| 85730 | <1% | 156 | $690.69 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 53 | $670.00 |
| 73130 | <1% | 13 | $616.42 | |
| 82962 | <1% | 153 | $496.00 | |
| 84100 | <1% | 146 | $484.34 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 74 | $345.73 |
| 85379 | <1% | 33 | $240.81 | |
| 80143 | <1% | 13 | $220.76 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 30 | $215.82 |
| 84145 | <1% | 12 | $213.24 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 40 | $196.38 |
| 80179 | <1% | 13 | $191.04 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 21 | $185.99 |
| 99000 | <1% | 16 | $176.12 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 18 | $153.77 |
| 87186 | <1% | 12 | $84.84 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16 | $78.87 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENNELLY, JOHN (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Sonoma Valley Health Care District | Sonoma, CA | $15K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.